GC Pharma announced on April 28 that it signed a development and option agreement with Acuitas Therapeutics of Canada to introduce lipid nano particle (LNP) technology.
The contract allows GC Pharma to use up to four LNP technologies owned by Acuitas to develop messenger RNA (mRNA) vaccines or therapeutics.
The LNP delivery system injects mRNA-based drugs into the body in the form of nanoparticles. It is a key technology that enables the development of mRNA-based drugs. In particular, LNP technology owned by Acuitas was applied to Pfizer’s COVID-19 vaccine “Comirnaty.”
Gloss